For­mer Akcea pres­i­dent makes the leap to CEO seat at Avid­i­ty Bio­sciences; Astel­las in­vests $12.5M in­to two in­cu­ba­tors

→ Af­ter it was an­nounced last week, in a sur­prise twist, that Akcea pres­i­dent Sarah Boyce along with her two top ex­ec col­leagues, CEO Paula Soteropou­los and COO Jef­frey Gold­berg were hit­ting the ex­it at the Io­n­is spin­off, Boyce has found a new home. Boyce has been tapped to the helm of Avid­i­ty Bio­sciences — a com­pa­ny pi­o­neer­ing an­ti­body-oligonu­cleotide con­ju­gates (AOCs) — as their new CEO, pres­i­dent and board mem­ber. Boyce will draw from ex­pe­ri­ence from her pre­vi­ous stints at Io­n­is, For­est Lab­o­ra­to­ries, Alex­ion Phar­ma­ceu­ti­cals, No­var­tis On­col­o­gy and Roche.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER